TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16241946
Drug: Enoxaparin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (30 mg b.i.d.)
Study: 16241946
Drug: BAY 59-7939
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 59-7939 (2.5-10 mg b.i.d.)
Study: 12133066
Drug: Vasal lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasal lavage with 50 mL of normal saline
Study: 2160414
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) injection of CY 216, 100 anti-factor Xa IC U/kg
Study: 2160414
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) injection of CY 216, 100 anti-factor Xa IC U/kg
Study: 31099219
Drug: Medication artificial
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication artificial menstrual cycle method (Femoston)
Study: 28829526
Drug: Morphine-ADER-IMT 60
Normalized name: morphine sulfate 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-ADER-IMT 60 mg
Study: 28829526
Drug: Morphine-ADER-IMT 30
Normalized name: morphine sulfate 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-ADER-IMT 30 mg
Study: 28829526
Drug: Morphine-ADER-IMT 2
Normalized name: morphine sulfate 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-ADER-IMT 2 ȕ 15 mg
Study: 28829526
Drug: Morphine-ADER-IMT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-ADER-IMT
Study: 9048348
Drug: Weekly subcutaneous
Normalized name: Weekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly subcutaneous (SC) rHuEPO at one third the weekly IV dose for 10 months
Study: 9048348
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous (IV) rHuEPO therapy
Study: 8315262
Drug: Ursodeoxycholic acid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid, 500 mg daily (about 8.7 mg/kg body weight)
Study: 3443140
Drug: Metoprolol tartrate
Normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol tartrate 100 mg orally
Study: 3443140
Drug: Metoprolol tartrate
Normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol tartrate 200 mg orally
Study: 3443140
Drug: Metoprolol tartrate
Normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol tartrate 20 mg as a constant‐rate intravenous infusion over 20 min
Study: 20724647
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g C10
Study: 20724647
Drug: 23 g
Normalized name: PEG-23 GLYCERYL DISTEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23 g C10
Study: 20724647
Drug: 23 g
Normalized name: PEG-23 GLYCERYL DISTEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23 g C10 (substituted for fats)
Study: 20724647
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g (control)
Study: 18272089
Drug: 24 mg
Normalized name: uracil 224 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg dexamethasone intravenously
Study: 15709187
Drug: mTOR kinase
Normalized name: Kinase (enzyme-activating), uro-urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: mTOR kinase inhibitor CCI‐779
Study: 12566371
Drug: Lisinopril (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (30 mg/d, median, range: 10 to 40 mg/d)
Study: 12566371
Drug: Lisinopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10 mg/d)
Study: 12566371
Drug: Lisinopril (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (maximum doses)
Study: 1896268
Drug: 0.1 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mL/kg of 1% lidocaine prior to the lumbar puncture
Study: 6414822
Drug: Indomethacin 100
Normalized name: indomethacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 100 mg/day for 2.5 days
Study: 6414822
Drug: Hydralazine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine 0.2 mg/kg intravenous injection after indomethacin
Study: 6414822
Drug: Hydralazine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine 0.2 mg/kg intravenous injection after placebo
Study: 28854208
Drug: Immediate group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate group (oral iron started concurrently with antimalarial treatment)
Study: 28854208
Drug: Delayed group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed group (oral iron started 28 days after antimalarial treatment)
Study: 25819861
Drug: Self-management intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management intervention conducted by a nurse focusing on medication goals, medication-symptom associations, and symptom response plan
Study: 15301924
Drug: Progesterone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (200 mg, two oral doses)
Study: 3325256
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment with ofloxacin during granulocytopenia after cytostatic treatment
Study: 3325256
Drug: Control phases
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control phases (no ofloxacin prophylaxis) during cytostatic treatment
Study: 3325256
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment with ofloxacin
Study: 2435449
Drug: Imipramine or
Normalized name: imipramine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine or amitriptyline (150 mg)
Study: 20108108
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate and glucosamine (1,600 mg oral mixture, twice daily for 8 months)
Study: 20108108
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily for 8 months)
Study: 17588298
Drug: Quarter-dose titration
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quarter-dose titration and acetaminophen
Study: 17588298
Drug: Quarter-dose titration
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quarter-dose titration and ibuprofen
Study: 17588298
Drug: Half-dose titration
Normalized name: Half Beta-Prograne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose titration and acetaminophen
Study: 17588298
Drug: Half-dose titration
Normalized name: Half Beta-Prograne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose titration and ibuprofen
Study: 17588298
Drug: Full-dose therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose therapy plus acetaminophen
Study: 17588298
Drug: No titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: No titration (control group)
Study: 10441974
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate via nebulizers at a dosage of 2 mg twice daily for 4 weeks
Study: 8527276
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cholestyramine ('Questran A')
Study: 786680
Drug: Ibuprofen (Brufen:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (Brufen: 400 mg three times daily)
Study: 28456141
Drug: Hormone use
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone use
Study: 26074708
Drug: Levofloxacin-doxycycline-based triple
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin-doxycycline-based triple therapy with Lactobacillus casei DG (n = 71)
Study: 26074708
Drug: Levofloxacin-doxycycline-based triple
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin-doxycycline-based triple therapy without Lactobacillus casei DG (n = 71)
Study: 21234550
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch (PL)
Study: 17095973
Drug: Inhaled nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitroglycerin (20 microg.kg(‐1))
Study: 17095973
Drug: Inhaled iloprost
Normalized name: iloprost Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled iloprost (2.5 microg.kg(‐1))
Study: 15155607
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol 200 micro g
Study: 15155607
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol 400 micro g
Study: 15155607
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol 800 micro g
Study: 369076
Drug: Ciclobendazole (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclobendazole (600 mg to 1200 mg)
Study: 15076014
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg adjunctive mirtazapine
Study: 30835436
Drug: Bicarbonate (0.40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate (0.40 g/kg)
Study: 28233458
Drug: β1-/β2-receptor-blockers (n=2219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: β1-/β2-receptor-blockers (n=2219)
Study: 28233458
Drug: High-dose β-blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose β-blockers (>25 mg carvedilol equivalent daily dose, n=1005)
Study: 21270723
Drug: Sequential injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential injection of 1.5% mepivacaine followed 90 secs later by 0.5% ropivacaine
Study: 21270723
Drug: Simultaneous injection
Normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous injection of 1.5% mepivacaine and 0.5% ropivacaine
Study: 10689268
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium (30 mg/kg)
Study: 20384753
Drug: Electrocoagulation (EC)
Normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrocoagulation (EC) treatment
Study: 15716163
Drug: First-degree biological
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-degree biological relatives of schizophrenia patients
Study: 11482924
Drug: Bisoprolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (5 mg x day(‐1))
Study: 10426452
Drug: Single-agent docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-agent docetaxel (Taxotere) 100 mg/m2 every 3 weeks
Study: 10426452
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy regimens (mitomycin C plus vinblastine, methotrexate plus 5‐fluorouracil, or 5‐fluorouracil plus vinorelbine)
Study: 31538401
Drug: StandingTall exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: StandingTall exercise program delivered through tablet computers for 12 weeks
Study: 28183567
Drug: Cormack-Lehane scores
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cormack-Lehane scores (C‐L)
Study: 22188311
Drug: Daily topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily topiramate
Study: 19958429
Drug: 5% niacinamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% niacinamide plus 1% N-undecylenoyl phenylalanine formulation
Study: 19958429
Drug: 5% niacinamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% niacinamide formulation
Study: 15320674
Drug: Dextrose treatment
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose treatment
Study: 15320674
Drug: Honey treatment
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey treatment
Study: 11282700
Drug: Dialectical behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical behavior therapy (DBT) for 20 weeks
Study: 9274581
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (antianginal drugs)
Study: 3103436
Drug: Etidronate, 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate, 7.5 mg/kg of body weight
Study: 31281981
Drug: Continuous perineural
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous perineural local anesthetic infusion (CPI) with ropivacaine 0.2% administered at 2 mL/h for 72 hours
Study: 31281981
Drug: Placebo (NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (NaCl 0.9%) administered at 2 mL/h for 72 hours
Study: 27475032
Drug: Technology-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technology-based intervention promoting adherence to controller medication (two computer-delivered sessions based on motivational interviewing combined with text message reminders)
Study: 21780974
Drug: 250 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ppm AmF/SnF(2) solution (Meridol) - extra-oral application
Study: 21780974
Drug: CPP-ACP crème
Normalized name: tocopherol acetate / vitamin A palmitate Topical Cream [Lazer Creme]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPP-ACP crème (Tooth Mousse) - extra-oral application
Study: 21780974
Drug: 250 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ppm AmF/SnF(2) solution (Meridol) - intra-oral application
Study: 21780974
Drug: CPP-ACP crème
Normalized name: tocopherol acetate / vitamin A palmitate Topical Cream [Lazer Creme]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPP-ACP crème (Tooth Mousse) - intra-oral application
Study: 17433732
Drug: Iloprost (intra-arterial,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost (intra-arterial, intra-operative bolus of 3000 ng, plus intravenous infusion of 0.5-2.0 ng/kg/min for six hours/day for 4-7 days following surgery)
Study: 10403597
Drug: VAQTA 25
Normalized name: Vaqta 25 UNT per 0.5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAQTA 25 U (3 doses)
Study: 10403597
Drug: HAVRIX 720
Normalized name: Havrix 720 UNT per 0.5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAVRIX 720 EU (3 doses)
Study: 7651666
Drug: Tocolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocolytic therapy (MgSO4 and terbutaline as first-line agents)
Study: 2275566
Drug: Netilmicin, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netilmicin, 3 doses
Study: 7371700
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal 50 g ingested within 5 min of taking the drugs
Study: 7371700
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal 118 g in 5 divided doses given between 10 and 48 hr after ingestion of phenobarbitone
Study: 19056618
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate (3000 mg/d)
Study: 17697359
Drug: Dextran-70 infusion
Normalized name: Dextran 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran-70 infusion at a dose of 7.5 ml/kg before cardiopulmonary bypass and 12.5 ml/kg after cessation of cardiopulmonary bypass
Study: 17697359
Drug: Dextran-70 infusion
Normalized name: Dextran 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran-70 infusion
Study: 17697359
Drug: Gelatin infusion
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin infusion (Control)
Study: 9745419
Drug: Testosterone patches
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone patches (5 mg testosterone over 24 h)
Study: 29433578
Drug: Sequential nephron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential nephron blockade (thiazide diuretic, aldosterone-receptor blocker, furosemide, amiloride)
Study: 29433578
Drug: Dual blockade
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual blockade of the RAAS (ACE inhibitor plus beta-blocker)
Study: 26463170
Drug: Culturally consistent
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally consistent diabetes educational program led by a Latino pastor, including weekly reviews of the American Diabetes Association's booklets on diabetes education.
Study: 25062874
Drug: Nafamostat (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafamostat (20 mg)
Study: 22399616
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² i.v. d1 q3 weeks (tT)
Study: 22399616
Drug: Docetaxel 50
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 50 mg/m² i.v. d1 and d 14, q4 weeks (bT)
Study: 20616541
Drug: Non-SCT (further
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-SCT (further intensive post-remission non-myeloablative chemotherapy or no further therapy)
Study: 15129752
Drug: Concurrent nontemporal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent nontemporal task
Study: 15129752
Drug: No concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: No concurrent task
Study: 8831331
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg/kg + 5 mg.kg‐1.h‐1)
Study: 1485475
Drug: Intravenous Actovegin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Actovegin 20% (250 ml daily infusion)
Study: 3934453
Drug: L-triiodothyronine (LT3)
Normalized name: L-3,5,3'-Triiodothyronine
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-triiodothyronine (LT3) administration
Study: 3934453
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no LT3 administration)
Study: 3934453
Drug: Sodium ipodate
Normalized name: ipodate sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ipodate administration
Study: 30245330
Drug: Cortisol administration
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol administration (20 mg hydrocortisone)
Study: 28854590
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg, increased to 5 mg if non-responders)
Study: 28854590
Drug: Clomiphene Citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene Citrate (CC) (50 mg, increased to 100 mg if non-responders)
Study: 17854590
Drug: linaclotide 1000
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: linaclotide 1000 microg once daily
Study: 17854590
Drug: linaclotide 100
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: linaclotide 100 microg once daily
Study: 11333130
Drug: DBDT regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBDT regimen (BCNU 150 mg/m2 i.v. on day 1, cisplatin 25 mg/m2 i.v. daily on days 1 to 3, DTIC 220 mg/m2 i.v. daily on days 1 to 3, tamoxifen 160 mg orally daily for 7 days prior to chemotherapy)
Study: 11333130
Drug: DTIC alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC alone (1200 mg/m2 i.v. on day 1, repeated every 21 days)
Study: 8239808
Drug: Antiplatelet drug
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet drug regimens
Study: 3120345
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate 20 mg four times daily
Study: 30217958
Drug: Inhaled nemiralisib
Normalized name: Nemiralisib
DrugBank: Nemiralisib (DB16253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nemiralisib (1000 µg)
Study: 27012781
Drug: Whole prasugrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole prasugrel 60-mg loading dose
Study: 24975869
Drug: Anticoagulant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant treatment eligibility
Study: 22619259
Drug: IV elinogrel
Normalized name: Elinogrel
DrugBank: Elinogrel (DB06350)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV elinogrel (120 mg) plus oral elinogrel (100 mg twice daily)
Study: 22619259
Drug: IV elinogrel
Normalized name: Elinogrel
DrugBank: Elinogrel (DB06350)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV elinogrel (120 mg) plus oral elinogrel (150 mg twice daily)
Study: 22619259
Drug: IV and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV and oral elinogrel
Study: 18584919
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity warfarin anticoagulation
Study: 18584919
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist anticoagulants
Study: 16159905
Drug: Early childhood
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early childhood stimulation intervention with weekly home visits by community health aides for one year.
Study: 9864073
Drug: pill placebo-case
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: pill placebo-case management (Pbo-CM)
Study: 9864073
Drug: cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: cognitive behavior therapy (CBT)
Study: 8536905
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg glucagon (Study 1)
Study: 8536905
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg glucagon (Study 2)
Study: 8536905
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg glucagon (both studies)
Study: 2302870
Drug: Subcutaneous (s.c.)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c.) administration of recombinant human erythropoietin (rHuEPO) at 50 U/kg body weight